MedTrace Logo

P53 in Differentiated Thyroid Cancer

NCT01954134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2013-10-01

No results posted yet for this study

Summary

In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

Conditions

  • Thyroid Neoplasms

Sponsors & Collaborators

  • Cumhuriyet University

    lead OTHER

Principal Investigators

  • Zekiye Hasbek, M.D. · Cumhuriyet University

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954134 on ClinicalTrials.gov